Efficacy and Safety of Direct‐Acting Oral Anticoagulants in Atrial Fibrillation With Hypertrophic Cardiomyopathy
Journal of the American Heart Association · 2026
DOI: 10.1161/jaha.125.045998 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Amro Taha und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology West Virginia University Morgantown WV USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Cardiomyopathy, Hypertrophic, Factor Xa Inhibitors, Thromboembolism. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Patients with hypertrophic cardiomyopathy (HCM) were excluded from pivotal trials comparing the efficacy and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists.
Methods
Our retrospective cohort study using the TriNetX database compared adults with HCM‐atrial fibrillation who initiated DOACs or vitamin K antagonists. The primary outcomes were all‐cause mortality and ischemic stroke/systemic thromboembolism. Secondary outcomes included major bleeding, intracranial hemorrhage, gastrointestinal bleeding, and all‐cause hospitalization. Subgroup analysis was conducted for obstructive HCM.
Results
Among 13 143 patients with HCM‐atrial fibrillation (2963 matched pairs). DOAC use was associated with lower all‐cause mortality (hazard ratio [HR], 0.82[ 95% CI, 0.73–0.93]; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology West Virginia University Morgantown WV USA.
- Department of Internal Medicine WVU Camden Clark Medical Center Parkersburg WV USA.
- Department of Internal Medicine Inspira Medical Center Vineland New Jersey USA.
- Department of Cardiovascular Medicine University of Texas San Antonio Texas USA.
- Division of Cardiovascular Medicine Oregon Health and Science University School of Medicine Portland Oregon USA.
ORCID-Profile: Avilash Mondal, Usman Ali Akbar, Aobo Li, Harigopal Sandhyavenu, Sittinun Thangjui, Harshith Thyagaturu, Christopher Bianco, Marco Caccamo, Ahmad Masri, Sudarshan Balla
Zitieren
APA
Taha, A., Mondal, A., Akbar, U. A., Li, A., Sandhyavenu, H., Alhajji, M., Thangjui, S., Thyagaturu, H., Bianco, C., Caccamo, M., Masri, A., & Balla, S. (2026). Efficacy and Safety of Direct‐Acting Oral Anticoagulants in Atrial Fibrillation With Hypertrophic Cardiomyopathy. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.045998
Vancouver
Taha A, Mondal A, Akbar UA, Li A, Sandhyavenu H, Alhajji M, et al. Efficacy and Safety of Direct‐Acting Oral Anticoagulants in Atrial Fibrillation With Hypertrophic Cardiomyopathy. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.045998
BibTeX
@article{Taha2026,
author = {Taha, Amro and Mondal, Avilash and Akbar, Usman Ali and Li, Aobo and Sandhyavenu, Harigopal and Alhajji, Mohamed and Thangjui, Sittinun and Thyagaturu, Harshith and Bianco, Christopher and Caccamo, Marco and Masri, Ahmad and Balla, Sudarshan},
title = {Efficacy and Safety of Direct‐Acting Oral Anticoagulants in Atrial Fibrillation With Hypertrophic Cardiomyopathy},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.125.045998}
}
EUVIMED